LEO Pharma’s Anzupgo cream progresses to phase 3 trial for lichen sclerosus
There are currently no approved treatments specifically indicated for LS in the US or Europe
- News
- Research
- Sales
- Regulatory
- Healthcare
- Marketing
LEO Pharma’s Anzupgo cream progresses to phase 3 trial for lichen sclerosus
There are currently no approved treatments specifically indicated for LS in the US or Europe
Lilly announces acquisition of Ventyx Biosciences for around $1.2bn
Multiple Ventyx drugs are currently in phase 2 development for inflammatory disease
AstraZeneca and Daiichi Sankyo’s Datroway given FDA Priority Review for breast cancer treatment
Approximately 70% of metastatic triple-negative breast cancer patients are ineligible for immunotherapy, creating an unmet medical need
Celebrating Excellence in Healthcare Partnerships Awards!
The Awards were sponsored by Inizio, Chase, druid and Robotics AI
Genentech increases investment to $2bn for US manufacturing site
Roche and Genentech have a current commitment of $50bn for US manufacturing
Latest content
ViCentra appoints Reman McDonagh as Vice President, Global Marketing
McDonagh has held senior leadership positions at Roche, Medtronic, Cellnovo and Insulet
Read More
TECregen appoints Klaas P Zuideveld as CEO
Zuideveld was most recently CEO of Versameb, and has held senior roles at Caris Life Sciences and Roche
Read More
Indegene appoints Jill DeSimone to Board of Directors
DeSimone was formerly President of US Oncology at Merck
Read More
Spyre Therapeutics appoints Kate Tansey Chevlen as Chief Commercial Officer
Tansey Chevlen previously spent over 17 years at Amgen in multiple leadership roles
Read More
Intelligence
Designing healthcare AI that works for every patient
As generative AI becomes more embedded in clinical decision-making, ensuring safety, accuracy and relevance is critical
Read More
Oral health and systemic disease: why they may be more closely linked than we thought
P. gingivalis, a type of bacteria found in the mouth, is linked to autoimmune diseases like rheumatoid arthritis
Read More
ASH 2025: where Magic Kingdom met the spirit of Andor
At ASH 2025, bold science and immersive experience bumped shoulders with a clear call to fight for patients
Read More
Alzheimer’s disease – the future of diagnosis and treatment in Europe
Recognising symptoms early and acting quickly can make a real difference to the lives of patients
Read More
Clinical trials on dementia: bridging access and innovation
Addressing the significant challenges surrounding the accessibility and availability of clinical trials
Read More
The trust crisis: how pharma must evolve to engage Gen Z HCPs
Trust isn’t a campaign outcome; it’s the product of behaviour, language and consistency
Read More
Blogs
Latest
Cuttsy+Cuttsy becomes employee owned
February 9, 2026 | Cuttsy + Cuttsy|EOT, Employee Ownership, agency, healthcare comms
Cuttsy+Cuttsy announces its transition to employee ownership, celebrating 15 years of prioritising clients, patients, and its team while continuing under the leadership of founders Caroline …
New Webinar: 2026 Engagement Strategies For Modern Pharma
February 5, 2026 | Impetus Digital|AI patient, Advisory Boards, HCP AI, HCP engagement, HCP virtual reality, Impetus Digital, Investigator Meetings, Learning module, MSL enablement, Product Launch, Virtual Engagement, digital fatigue, health innovation, health tech, medical education, pharma webinar, virtual education, webinar
Turn interaction into intelligence! Don’t miss this chance to lead the industry with our free pharma-exclusive webinar!
Why Sleep Health is the Missing Link in Women’s Wellness
February 5, 2026 | Medscape Education|Women in Leadership, Women in healthcare
While obstructive sleep apnea (OSA) affects approximately 32% of US adults—nearly 80 million people—it remains an “epidemic hiding in plain sight”. Perhaps most staggering is …
MFN Pricing Is Moving Fast – Here’s What Matters
February 3, 2026 | Genesis Research Group|Access, GENEROUS, GLOBE, GUARD, IRA, Market Access, Pricing, mfn, most favored nation, most-favoured nation
With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it’s a lot …
ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment
January 27, 2026 | Genesis Research Group|HEOR, Market Access, RWE, Top Trends, ispor, organization
In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability …
How can pharma build genuine partnerships with patient communities?
January 19, 2026 | Amiculum|patient advocacy, patient engagement
Patient engagement is not optional in pharma – it’s integral. Meaningful partnerships with patients, caregivers and advocates must shape every stage of healthcare and medicines …
Five Predictions That Will Reshape Biopharma Commercialisation in 2026
January 5, 2026 | Nmblr|
Every year, we’re met with restructuring, hiring freezes, and portfolio cuts. And every year we tell ourselves the same story. It’s a rough patch. A …
What will healthcare communications look like in 2026? Amiculum’s prediction of upcoming trends
December 16, 2025 | Amiculum|AI, JCA, Market Access, Patient-integrated Communications, VuuAI, genAI, healthcare communications, misinformation, omnichannel, trends
By Sarah Theobald
Clinical research in 2026: The trends shaping tomorrow
December 16, 2025 | Cuttsy + Cuttsy|Communications, Decentralised trials, Digital, Pharma, advocacy, clinical trials, partnerships, patient engagement
Discover the key trends shaping clinical research in 2026, from patient-centric approaches to empowering site staff and fostering stronger human connections.
AI persona generation for healthcare: quick wins & real-world impact
December 4, 2025 | Amiculum|AI, Persona generation, Segmentation, artificial intelligence, healthcare communications, omnichannel
By Aaron Fletcher